Ortho-biologics company Royal Biologics launched Magnus, a DMSO-free viable cellular bone allograft, the first of its kind to be DMSO-free.
Magnus uses viable spine-derived cells from the vertebral region and preserves them with a DMSO-free cryoprotectant. DMSO has been linked to post-transplant complications. Surgeons can use Magnus in bone graft-based procedures.
Researchers studied the Magnus Viable Allograft's performance in 75 consecutive TLIF fusions. The procedure had a 96 percent fusion rate, with 75 patients undergoing a total of 85 levels fused at 12 months, according to a study published in the International Journal of Spine Surgery.